Moderna stock pops after company makes regulatory submissions in U.S., Europe, Switzerland and Australia for its RSV vaccine

Moderna Inc.’s stock MRNA rose 3% Wednesday, after the company said it has made regulatory submissions in Europe, Switzerland and Australia for its mRNA-1345 vaccine which targets  RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency, Swissmedic in Switzerland, and the Therapeutic Goods Administration in Australia. The company has also initiated the rolling submission process for a Biologics License Application to the U.S. Food and Drug…